Koninklijke Philips (NYSE:PHG) Receives Average Rating of “Hold” from Analysts

Koninklijke Philips (NYSE:PHG) has been assigned a consensus rating of “Hold” from the four research firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company.

Several equities research analysts have recently commented on PHG shares. Jefferies Financial Group raised shares of Koninklijke Philips from an “underperform” rating to a “hold” rating in a research report on Tuesday. StockNews.com raised Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Monday, July 15th.

Koninklijke Philips Stock Down 15.9 %

Shares of NYSE:PHG opened at $26.62 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.74 and a current ratio of 1.16. Koninklijke Philips has a 52-week low of $18.47 and a 52-week high of $32.91. The business’s 50 day simple moving average is $31.05 and its two-hundred day simple moving average is $27.83. The firm has a market cap of $25.02 billion, a P/E ratio of -50.23, a PEG ratio of 1.04 and a beta of 0.74.

Koninklijke Philips (NYSE:PHG) last announced its quarterly earnings results on Monday, July 29th. The technology company reported $0.32 EPS for the quarter. Koninklijke Philips had a negative net margin of 2.35% and a positive return on equity of 10.15%. The business had revenue of $4.80 billion during the quarter. As a group, research analysts forecast that Koninklijke Philips will post 1.59 EPS for the current fiscal year.

Institutional Trading of Koninklijke Philips

Several institutional investors have recently made changes to their positions in PHG. Mondrian Investment Partners LTD boosted its holdings in Koninklijke Philips by 45.1% during the first quarter. Mondrian Investment Partners LTD now owns 9,553,058 shares of the technology company’s stock worth $191,061,000 after purchasing an additional 2,971,008 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Koninklijke Philips by 822.0% in the 2nd quarter. Millennium Management LLC now owns 1,120,521 shares of the technology company’s stock worth $28,237,000 after buying an additional 998,995 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Koninklijke Philips by 27.3% in the second quarter. Dimensional Fund Advisors LP now owns 4,036,336 shares of the technology company’s stock valued at $101,718,000 after acquiring an additional 864,951 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Koninklijke Philips by 361.7% in the first quarter. Jane Street Group LLC now owns 629,136 shares of the technology company’s stock valued at $12,583,000 after acquiring an additional 492,881 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Koninklijke Philips by 36.4% during the first quarter. Russell Investments Group Ltd. now owns 1,410,067 shares of the technology company’s stock valued at $28,201,000 after acquiring an additional 376,244 shares during the last quarter. Institutional investors own 13.67% of the company’s stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.